title: The future of melanoma therapy: developing new drugs and improving the use of old ones.
authors.affiliation: Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy.
authors.forename: Giuliano
authors.initials: G
authors.lastname: Palumbo
authors.affiliation: Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.affiliation: Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy.
authors.forename: Margaret
authors.initials: M
authors.lastname: Ottaviano
authors.affiliation: Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Damiano
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D000074324:Ipilimumab / Q000627:therapeutic use; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors; D048370:MAP Kinase Kinase 2 / Q000037:antagonists & inhibitors; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D000077594:Nivolumab; D010091:Oximes / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D011728:Pyridones / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D001384:Azetidines; D007093:Imidazoles; D007211:Indoles; D000074324:Ipilimumab; D010091:Oximes; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D000077484:Vemurafenib; D000077594:Nivolumab; C560077:trametinib; C000594389:atezolizumab; C582435:pembrolizumab; D048493:Proto-Oncogene Proteins B-raf; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; C574276:cobimetinib; C561627:dabrafenib
keywords: MEK inhibitor; adjuvant treatment; adoptive cell therapy; biological therapy; checkpoint inhibitors; immunotherapy; ipilimumab; melanoma; target therapy BRAF inhibitor